Comparison 7. Antacids versus placebo or no prophylaxis.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Clinically important upper GI bleeding	8	774	Risk Ratio (M‐H, Random, 95% CI)	0.49 [0.25, 0.99]
1.1 Antacids vs placebo	2	145	Risk Ratio (M‐H, Random, 95% CI)	2.04 [0.72, 5.79]
1.2 Antacids vs no prophylaxis	6	629	Risk Ratio (M‐H, Random, 95% CI)	0.35 [0.20, 0.60]
2 All‐cause mortality in ICU	2	300	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.53, 1.96]
2.1 Antacids vs no prophylaxis	2	300	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.53, 1.96]
3 All‐cause mortality in hospital	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
3.1 Antacids vs no prophylaxis	1		Risk Ratio (M‐H, Fixed, 95% CI)	0.0 [0.0, 0.0]
4 Number of participants requiring blood transfusions	2		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
4.1 Antacids vs no prophylaxis	2	226	Risk Ratio (M‐H, Fixed, 95% CI)	0.94 [0.30, 2.96]
5 Adverse events of interventions	4		Risk Ratio (M‐H, Fixed, 95% CI)	Subtotals only
5.1 Diarrhoea	4	395	Risk Ratio (M‐H, Fixed, 95% CI)	3.56 [1.83, 6.94]
5.2 Hypomagnesaemia	1	25	Risk Ratio (M‐H, Fixed, 95% CI)	3.75 [0.17, 84.02]
5.3 Hypophosphataemia	2	225	Risk Ratio (M‐H, Fixed, 95% CI)	5.48 [1.81, 16.61]
5.4 Hypermagnesaemia	1	100	Risk Ratio (M‐H, Fixed, 95% CI)	6.73 [0.36, 127.02]
5.5 Nausea and vomiting	3	370	Risk Ratio (M‐H, Fixed, 95% CI)	2.39 [0.86, 6.64]
5.6 Mental confusion	1	200	Risk Ratio (M‐H, Fixed, 95% CI)	1.27 [0.61, 2.67]
5.7 Creatinine increase	1	200	Risk Ratio (M‐H, Fixed, 95% CI)	1.17 [0.73, 1.87]